Toll Free: 1-888-928-9744

Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2016

Published: Apr 13, 2016 | Pages: 91 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Varicella Zoster (HHV-3) Infections - Pipeline Review, H1 2016', provides an overview of the Varicella Zoster (HHV-3) Infections pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Varicella Zoster (HHV-3) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Varicella Zoster (HHV-3) Infections and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Varicella Zoster (HHV-3) Infections
- The report reviews pipeline therapeutics for Varicella Zoster (HHV-3) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Varicella Zoster (HHV-3) Infections therapeutics and enlists all their major and minor projects
- The report assesses Varicella Zoster (HHV-3) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Varicella Zoster (HHV-3) Infections

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Varicella Zoster (HHV-3) Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Varicella Zoster (HHV-3) Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Content
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Varicella Zoster (HHV-3) Infections Overview 9 Therapeutics Development 10 Pipeline Products for Varicella Zoster (HHV-3) Infections - Overview 10 Pipeline Products for Varicella Zoster (HHV-3) Infections - Comparative Analysis 11 Varicella Zoster (HHV-3) Infections - Therapeutics under Development by Companies 12 Varicella Zoster (HHV-3) Infections - Therapeutics under Investigation by Universities/Institutes 14 Varicella Zoster (HHV-3) Infections - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Varicella Zoster (HHV-3) Infections - Products under Development by Companies 19 Varicella Zoster (HHV-3) Infections - Products under Investigation by Universities/Institutes 20 Varicella Zoster (HHV-3) Infections - Companies Involved in Therapeutics Development 21 Astellas Pharma Inc. 21 Beijing Minhai Biotechnology Co., Ltd 22 Beijing Tiantan Biological Products Co., Ltd. 23 China National Pharmaceutical Group Corporation 24 ContraVir Pharmaceuticals, Inc. 25 Epiphany Biosciences, Inc. 26 Foamix Pharmaceuticals Ltd. 27 GeneOne Life Science, Inc. 28 GlaxoSmithKline Plc 29 Green Cross Corporation 30 Merck & Co., Inc. 31 NAL Pharmaceuticals Ltd. 32 ReceptoPharm, Inc. 33 Sinovac Biotech Ltd. 34 TSRL, Inc. 35 Zydus Cadila Healthcare Limited 36 Varicella Zoster (HHV-3) Infections - Therapeutics Assessment 37 Assessment by Monotherapy Products 37 Assessment by Combination Products 38 Assessment by Target 39 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 (measles + mumps + rubella + varicella) (tetravalent) vaccine - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 (measles + mumps + rubella + varicella) vaccine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 (measles + rubella + varicella) vaccine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 acyclovir - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 amenamevir - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 chickenpox vaccine - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 FV-100 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 GLS-5100 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 GSK-1437173A - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 herpes zoster vaccine - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 HHV-3 vaccine - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 measles + mumps + rubella + varicella vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 MG-1111 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 NAL-3221 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 NAL-3223 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 RKP-00156 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 RPI-78M - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 sattabacin - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 TSR-087 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 V-212 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 valomaciclovir stearate - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 varicella zoster vaccine - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Varicella Zoster (HHV-3) Infections - Recent Pipeline Updates 74 Varicella Zoster (HHV-3) Infections - Dormant Projects 80 Varicella Zoster (HHV-3) Infections - Discontinued Products 81 Varicella Zoster (HHV-3) Infections - Product Development Milestones 82 Featured News & Press Releases 82 Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study 82 Oct 27, 2015: GSK's candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over 82 Oct 26, 2015: Sinovac Receives Clinical Trial Approval for Varicella Vaccine Candidate 83 Sep 08, 2015: Clinical trial for Cardiff's shingles treatment 84 Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain 85 Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial 85 Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied 86 Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN 87 Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint 87 Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant 88 Appendix 90 Methodology 90 Coverage 90 Secondary Research 90 Primary Research 90 Expert Panel Validation 90 Contact Us 90 Disclaimer 91
List of Tables
Number of Products under Development for Varicella Zoster (HHV-3) Infections, H1 2016 10 Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Comparative Analysis by Unknown Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Investigation by Universities/Institutes, H1 2016 20 Varicella Zoster (HHV-3) Infections - Pipeline by Astellas Pharma Inc., H1 2016 21 Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 22 Varicella Zoster (HHV-3) Infections - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2016 23 Varicella Zoster (HHV-3) Infections - Pipeline by China National Pharmaceutical Group Corporation, H1 2016 24 Varicella Zoster (HHV-3) Infections - Pipeline by ContraVir Pharmaceuticals, Inc., H1 2016 25 Varicella Zoster (HHV-3) Infections - Pipeline by Epiphany Biosciences, Inc., H1 2016 26 Varicella Zoster (HHV-3) Infections - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 27 Varicella Zoster (HHV-3) Infections - Pipeline by GeneOne Life Science, Inc., H1 2016 28 Varicella Zoster (HHV-3) Infections - Pipeline by GlaxoSmithKline Plc, H1 2016 29 Varicella Zoster (HHV-3) Infections - Pipeline by Green Cross Corporation, H1 2016 30 Varicella Zoster (HHV-3) Infections - Pipeline by Merck & Co., Inc., H1 2016 31 Varicella Zoster (HHV-3) Infections - Pipeline by NAL Pharmaceuticals Ltd., H1 2016 32 Varicella Zoster (HHV-3) Infections - Pipeline by ReceptoPharm, Inc., H1 2016 33 Varicella Zoster (HHV-3) Infections - Pipeline by Sinovac Biotech Ltd., H1 2016 34 Varicella Zoster (HHV-3) Infections - Pipeline by TSRL, Inc., H1 2016 35 Varicella Zoster (HHV-3) Infections - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 36 Assessment by Monotherapy Products, H1 2016 37 Assessment by Combination Products, H1 2016 38 Number of Products by Stage and Target, H1 2016 40 Number of Products by Stage and Mechanism of Action, H1 2016 42 Number of Products by Stage and Route of Administration, H1 2016 44 Number of Products by Stage and Molecule Type, H1 2016 46 Varicella Zoster (HHV-3) Infections Therapeutics - Recent Pipeline Updates, H1 2016 74 Varicella Zoster (HHV-3) Infections - Dormant Projects, H1 2016 80 Varicella Zoster (HHV-3) Infections - Discontinued Products, H1 2016 81


List of Figures
Number of Products under Development for Varicella Zoster (HHV-3) Infections, H1 2016 10 Number of Products under Development for Varicella Zoster (HHV-3) Infections - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Products, H1 2016 17 Assessment by Monotherapy Products, H1 2016 37 Assessment by Combination Products, H1 2016 38 Number of Products by Targets, H1 2016 39 Number of Products by Stage and Targets, H1 2016 39 Number of Products by Mechanism of Actions, H1 2016 41 Number of Products by Stage and Mechanism of Actions, H1 2016 41 Number of Products by Routes of Administration, H1 2016 43 Number of Products by Stage and Routes of Administration, H1 2016 43 Number of Products by Molecule Types, H1 2016 45 Number of Products by Stage and Molecule Types, H1 2016 45

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global dem

Read More...

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...

Global data center UPS market size is estimated to reach USD 5.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Declining tolerance levels pertaining to data loss along with amplifying acceptance of cloud computing is likely

Read More...

Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving cream

Read More...

Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealan

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify